Australia Accused Of Delay In Coverage Of Key Drugs For Budget Reasons
This article was originally published in PharmAsia News
Australia’s Pharmaceutical Benefits Scheme plans more than 40 changes in drug coverage that Health Minister Nicola Roxon said would benefit more than 160,000 Aussie patients.
You may also be interested in...
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.